These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 26142357)

  • 1. A National Approach to Reimbursement Decision-Making on Drugs for Rare Diseases in Canada? Insights from Across the Ponds.
    Short H; Stafinski T; Menon D
    Healthc Policy; 2015 May; 10(4):24-46. PubMed ID: 26142357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reimbursement of Drugs for Rare Diseases through the Public Healthcare System in Canada: Where Are We Now?
    Menon D; Clark D; Stafinski T
    Healthc Policy; 2015 Aug; 11(1):15-32. PubMed ID: 26571466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HTA decision-making for drugs for rare diseases: comparison of processes across countries.
    Stafinski T; Glennie J; Young A; Menon D
    Orphanet J Rare Dis; 2022 Jul; 17(1):258. PubMed ID: 35804398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engaging the Canadian public on reimbursement decision-making for drugs for rare diseases: a national online survey.
    Polisena J; Burgess M; Mitton C; Lynd LD
    BMC Health Serv Res; 2017 May; 17(1):372. PubMed ID: 28549479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrating public preferences into national reimbursement decisions: a descriptive comparison of approaches in Belgium and New Zealand.
    Leopold C; Lu CY; Wagner AK
    BMC Health Serv Res; 2020 Apr; 20(1):351. PubMed ID: 32334579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors associated with positive and negative recommendations for cancer and non-cancer drugs for rare diseases in Canada.
    Nagase FNI; Stafinski T; Sun J; Jhangri G; Menon D
    Orphanet J Rare Dis; 2019 Jun; 14(1):127. PubMed ID: 31174574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Involving patients in reducing decision uncertainties around orphan and ultra-orphan drugs: a rare opportunity?
    Menon D; Stafinski T; Dunn A; Short H
    Patient; 2015 Feb; 8(1):29-39. PubMed ID: 25516506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health technology assessment and price negotiation alignment for rare disorder drugs in Canada: Who benefits?
    Rawson NSB
    Orphanet J Rare Dis; 2022 Jun; 17(1):218. PubMed ID: 35698235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Historical and projected public spending on drugs for rare diseases in Canada between 2010 and 2025.
    Lech R; Chow G; Mann K; Mott P; Malmberg C; Forte L
    Orphanet J Rare Dis; 2022 Oct; 17(1):371. PubMed ID: 36209128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health technology assessment of drugs for rare diseases: insights, trends, and reasons for negative recommendations from the CADTH common drug review.
    Janoudi G; Amegatse W; McIntosh B; Sehgal C; Richter T
    Orphanet J Rare Dis; 2016 Dec; 11(1):164. PubMed ID: 27908281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk management frameworks for human health and environmental risks.
    Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
    J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The value and consequences of using public health technology assessments for private payer decision-making in Canada: one size does not fit all.
    Pericleous L; Amin M; Goeree R
    J Med Econ; 2019 May; 22(5):478-487. PubMed ID: 30757934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A synthesis of drug reimbursement decision-making processes in organisation for economic co-operation and development countries.
    Barnieh L; Manns B; Harris A; Blom M; Donaldson C; Klarenbach S; Husereau D; Lorenzetti D; Clement F
    Value Health; 2014; 17(1):98-108. PubMed ID: 24438723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health Technology Assessment (HTA) Case Studies: Factors Influencing Divergent HTA Reimbursement Recommendations in Australia, Canada, England, and Scotland.
    Allen N; Walker SR; Liberti L; Salek S
    Value Health; 2017 Mar; 20(3):320-328. PubMed ID: 28292476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Common Drug Review: a NICE start for Canada?
    McMahon M; Morgan S; Mitton C
    Health Policy; 2006 Aug; 77(3):339-51. PubMed ID: 16214257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Effectiveness of Integrated Care Pathways for Adults and Children in Health Care Settings: A Systematic Review.
    Allen D; Gillen E; Rixson L
    JBI Libr Syst Rev; 2009; 7(3):80-129. PubMed ID: 27820426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An impact analysis of the implementation of health technology assessment for new treatment of orphan diseases in Japan.
    Kogushi K; Ogawa T; Ikeda S
    Expert Rev Pharmacoecon Outcomes Res; 2020 Oct; 20(5):455-471. PubMed ID: 31496361
    [No Abstract]   [Full Text] [Related]  

  • 18. Why orphan drug coverage reimbursement decision-making needs patient and public involvement.
    Douglas CM; Wilcox E; Burgess M; Lynd LD
    Health Policy; 2015 May; 119(5):588-96. PubMed ID: 25641123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. International experiences in multicriteria decision analysis (MCDA) for evaluating orphan drugs: a scoping review.
    Lasalvia P; Prieto-Pinto L; Moreno M; Castrillón J; Romano G; Garzón-Orjuela N; Rosselli D
    Expert Rev Pharmacoecon Outcomes Res; 2019 Aug; 19(4):409-420. PubMed ID: 31210065
    [No Abstract]   [Full Text] [Related]  

  • 20. A case study of ex ante, value-based price and reimbursement decision-making: TLV and rimonabant in Sweden.
    Persson U; Willis M; Odegaard K
    Eur J Health Econ; 2010 Apr; 11(2):195-203. PubMed ID: 19639352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.